Literature DB >> 1611784

I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity.

R A Valdés Olmos1, W W ten Bokkel Huinink, J C Greve, C A Hoefnagel.   

Abstract

In six patients with doxorubicin-related cardiotoxicity, the severity of decrease in left ventricle ejection fraction (LVEF) was associated with faster myocardial I-123 MIBG washout rates. In four patients with severely decreased LVEF (range 19% to 28%), the 4-hour washout rate varied from 43% to 56%. In two patients with moderate cardiotoxicity (LVEF 42% and 43%), the washout rates were 37% and 35%, respectively. In contrast, in another patient thought to have initial left ventricular dysfunction (LVEF dropped from 66% to 54%), the myocardial I-123 MIBG retention rate was not reduced (6% washout). Subsequent continuation of chemotherapy in this patient was without complication. Reduced I-123 MIBG uptake in the left ventricle generally correlated with areas with abnormal Fourier amplitude values, but in one of the patients with moderate cardiotoxicity, the I-123 MIBG uptake was not reduced in a region with loss of amplitude, indicating dysfunction but probably no myocardial denervation. Analysis of the regional myocardial retention in patients with cardiotoxicity showed no significant difference in the I-123 MIBG washout rates of both segments with or without loss of amplitude. These data suggest that in spite of a localized loss of ventricular function demonstrated by radionuclide angiocardiography, doxorubicin-related cardiotoxicity appears to be based on a global process of myocardial adrenergic derangement.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611784     DOI: 10.1097/00003072-199203000-00001

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

1.  Anthracycline-induced cardiomyopathy: The search continues.

Authors:  Agnes S Kim; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2015-12-08       Impact factor: 5.952

2.  123I-MIBG myocardial scintigraphy as a noninvasive screen for the diagnosis of coronary artery spasm.

Authors:  J W Ha; J D Lee; Y Jang; N Chung; J Kwan; S J Rim; Y J Lee; W H Shim; S Y Cho; S S Kim
Journal:  J Nucl Cardiol       Date:  1998 Nov-Dec       Impact factor: 5.952

Review 3.  Cardio-oncology: the Nuclear Option.

Authors:  Jorge A Alvarez; Raymond R Russell
Journal:  Curr Cardiol Rep       Date:  2017-04       Impact factor: 2.931

Review 4.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

5.  Assessing anthracycline cardiotoxicity in the 1990s.

Authors:  I Carrió; M Estorch; A López-Pousa
Journal:  Eur J Nucl Med       Date:  1996-04

6.  Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging.

Authors:  Y Takeishi; H Sukekawa; T Sakurai; H Saito; S Nishimura; T Shibu; Y Sasaki; H Tomoike
Journal:  Ann Nucl Med       Date:  1994-08       Impact factor: 2.668

7.  Anthracyclines and the heart.

Authors:  P Thomas
Journal:  Br Heart J       Date:  1994-09

8.  The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.

Authors:  Raymond R Russell; Jonathan Alexander; Diwakar Jain; Indu G Poornima; Ajay V Srivastava; Eugene Storozynsky; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2016-06-01       Impact factor: 5.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.